Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • Heme · CLL, LymphomaRecruitingPhase 3NCT07321652

    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    Alliance for Clinical Trials in Oncology · 261 locations · Updated 2026-11-03

  • Heme · CLL, LymphomaRecruitingPhase 3NCT06943872

    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    BeOne Medicines · 195 locations · Updated 2026-10-23

  • Heme · CLLRecruitingPhase 3NCT07277231

    A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

    BeOne Medicines · 115 locations · Updated 2026-09-28

  • Heme · CLLNot yet recruitingPhase 2NCT07819214

    Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

    University of California, Irvine · 1 locations · Updated 2026-11-09

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07734038

    Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    Kerry Rogers · 1 locations · Updated 2026-11-09

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07582159

    Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    City of Hope Medical Center · 2 locations · Updated 2026-11-06

  • Heme · CLL, LymphomaRecruitingPhase 2NCT03516617

    Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Mayo Clinic · 3 locations · Updated 2026-10-26

  • Heme · CLL, LymphomaRecruitingPhase 2NCT04941716

    Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-23

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07887061

    Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-21

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07557056

    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Jennifer Woyach · 1 locations · Updated 2026-10-15

  • Heme · CLL, LymphomaRecruitingPhase 1 / Phase 2NCT05791409

    Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

    Stichting Hemato-Oncologie voor Volwassenen Nederland · 29 locations · Updated 2026-10-05

  • Heme · CLLRecruitingPhase 2NCT04523428

    REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

    Stichting Hemato-Oncologie voor Volwassenen Nederland · 18 locations · Updated 2026-09-21

  • Heme · CLL, LymphomaRecruitingPhase 2NCT04169737

    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-09-10

  • Heme · CLLRecruitingPhase 2NCT07566364

    Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-08-12

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06849713

    Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

    Massachusetts General Hospital · 2 locations · Updated 2026-08-11

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07744750

    Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma

    Changzhou No.2 People's Hospital · 1 locations · Updated 2026-08-06

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07738887

    Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

    The Lymphoma Academic Research Organisation · 29 locations · Updated 2026-07-31

  • Heme · CLL, LymphomaRecruitingPhase 1 / Phase 2NCT07609862

    A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

    Guangzhou Lupeng Pharmaceutical Company LTD. · 1 locations · Updated 2026-07-30

  • Heme · CLLNot yet recruitingPhase 2NCT07690891

    Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

    Medical College of Wisconsin · 1 locations · Updated 2026-07-08

  • Heme · CLLNot yet recruitingPhase 2NCT07682415

    Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0

    Yi Shuhua · 7 locations · Updated 2026-07-02

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07671378

    A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

    The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2026-06-26

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 2NCT03314974

    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06544785

    Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    PETHEMA Foundation · 19 locations · Updated 2026-06-25

  • Heme · CLLRecruitingPhase 2NCT07271667

    A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

    Curis, Inc. · 11 locations · Updated 2026-06-12

  • Heme · CLLNot yet recruitingPhase 2NCT07624799

    Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

    French Innovative Leukemia Organisation · Locations not reported · Updated 2026-06-03

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07218510

    Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

    City of Hope Medical Center · 7 locations · Updated 2026-03-13

  • Heme · CLL, LymphomaRecruitingPhase 2NCT05336812

    Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

    Ohio State University Comprehensive Cancer Center · 1 locations · Updated 2026-02-19

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06466122

    Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

    Kerry Rogers · 1 locations · Updated 2026-02-19

  • Heme · CLLRecruitingPhase 1 / Phase 2NCT06644183

    Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

    Jennifer R. Brown, MD, PhD · 1 locations · Updated 2026-02-11

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07108998

    Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

    Zulfa Omer · 1 locations · Updated 2026-01-06

  • Heme · CLL, LymphomaRecruitingPhase 1 / Phase 2NCT07052695

    Mosunetuzumab for CLL MRD Clearance

    Inhye Ahn · 2 locations · Updated 2025-12-15

  • Heme · CLL, LymphomaRecruitingPhase 2NCT05168930

    Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

    Dana-Farber Cancer Institute · 4 locations · Updated 2025-12-05

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06958705

    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

    The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2025-11-25

  • Heme · CLLNot yet recruitingPhase 2NCT07003464

    Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

    The First Hospital of Jilin University · 1 locations · Updated 2025-06-04

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT06367374

    MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2024-04-16

  • Heme · CLLRecruitingPhase 2NCT04758975

    Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

    Paolo Ghia · 1 locations · Updated 2023-10-04

  • Heme · CLLRecruitingPhase 2NCT04908228

    Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

    Paolo Ghia · 1 locations · Updated 2023-10-03

  • Heme · CLL, LymphomaRecruitingNot reportedObservationalNCT07774390

    Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL

    European Research Initiative on CLL · 1 locations · Updated 2026-08-19

  • Heme · CLL, LymphomaRecruitingPhase 1NCT05943496

    Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

    OHSU Knight Cancer Institute · 1 locations · Updated 2025-11-06

  • Heme · CLLNot yet recruitingNot reportedObservationalNCT07162532

    Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients

    Assiut University · Locations not reported · Updated 2025-09-09

Showing 1–40 of 41. Older studies

More hematologic trials (21) that list MRD only as a secondary endpoint
  • Heme · CLL, LymphomaRecruitingPhase 3NCT05947851

    A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    Merck Sharp & Dohme LLC · 107 locations · Updated 2026-11-17

  • Heme · CLLRecruitingPhase 3NCT05197192

    A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

    German CLL Study Group · 30 locations · Updated 2026-08-20

  • Heme · CLL, LymphomaRecruitingPhase 3NCT06319456

    A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

    Ascentage Pharma Group Inc. · 10 locations · Updated 2026-07-28

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06520098

    A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    VA Office of Research and Development · 4 locations · Updated 2026-10-30

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07024706

    MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

    AstraZeneca · 47 locations · Updated 2026-10-23

  • Heme · CLLRecruitingPhase 2NCT06043674

    Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

    Christine Ryan · 5 locations · Updated 2026-10-21

  • Heme · CLLNot yet recruitingPhase 1 / Phase 2NCT07847957

    Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

    Dana-Farber Cancer Institute · 2 locations · Updated 2026-09-29

  • Heme · CLLNot yet recruitingPhase 2NCT07831395

    Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL

    Institute of Hematology & Blood Diseases Hospital, China · 6 locations · Updated 2026-09-21

  • Heme · ALL, CLL, LymphomaNot yet recruitingPhase 2NCT07812246

    Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial

    City of Hope Medical Center · 3 locations · Updated 2026-09-10

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07526597

    Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors

    UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-08-05

  • Heme · CLL, LymphomaNot yet recruitingPhase 2NCT07459608

    Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma

    Henan Cancer Hospital · 1 locations · Updated 2026-07-29

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07523555

    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

    Beijing Biotech · 1 locations · Updated 2026-04-13

  • Heme · CLLRecruitingPhase 2NCT04895436

    Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

    AbbVie · 58 locations · Updated 2026-02-09

  • Heme · CLL, LymphomaRecruitingPhase 2NCT07014917

    Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

    Zulfa Omer · 1 locations · Updated 2026-01-06

  • Heme · CLL, LymphomaRecruitingPhase 2NCT06978088

    LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

    Zulfa Omer · 1 locations · Updated 2025-08-14

  • Heme · ALL, CLL, LymphomaRecruitingPhase 2NCT05281809

    Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    John Lister · 1 locations · Updated 2025-01-13

  • Heme · CLLRecruitingPhase 2NCT03980002

    A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2019-06-10

  • Heme · CLL, AMLNot yet recruitingPhase 1NCT07897136

    CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia

    Liping Dou · 1 locations · Updated 2026-10-27

  • Heme · CLL, AMLNot yet recruitingPhase 1NCT07841002

    CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia

    Liping Dou · 1 locations · Updated 2026-10-02

  • Heme · CLL, LymphomaRecruitingPhase 1NCT04892277

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

    Mayo Clinic · 1 locations · Updated 2026-06-09

  • Heme · CLL, LymphomaNot yet recruitingNot applicableNCT07286539

    Precision Physical Exercise for Personalized Onco-Hematology.

    University of Salamanca · Locations not reported · Updated 2025-12-16

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.